JP2007526300A - 医薬化合物 - Google Patents

医薬化合物 Download PDF

Info

Publication number
JP2007526300A
JP2007526300A JP2007501740A JP2007501740A JP2007526300A JP 2007526300 A JP2007526300 A JP 2007526300A JP 2007501740 A JP2007501740 A JP 2007501740A JP 2007501740 A JP2007501740 A JP 2007501740A JP 2007526300 A JP2007526300 A JP 2007526300A
Authority
JP
Japan
Prior art keywords
arg
group
formula
ile
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007501740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007526300A5 (cg-RX-API-DMAC7.html
Inventor
ロハーグ,ダグフィン
Original Assignee
ジーイー・ヘルスケア・アクスイェ・セルスカプ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーイー・ヘルスケア・アクスイェ・セルスカプ filed Critical ジーイー・ヘルスケア・アクスイェ・セルスカプ
Publication of JP2007526300A publication Critical patent/JP2007526300A/ja
Publication of JP2007526300A5 publication Critical patent/JP2007526300A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007501740A 2004-03-04 2005-03-03 医薬化合物 Pending JP2007526300A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20040953 2004-03-04
PCT/NO2005/000078 WO2005084715A2 (en) 2004-03-04 2005-03-03 Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy

Publications (2)

Publication Number Publication Date
JP2007526300A true JP2007526300A (ja) 2007-09-13
JP2007526300A5 JP2007526300A5 (cg-RX-API-DMAC7.html) 2008-04-17

Family

ID=34918859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007501740A Pending JP2007526300A (ja) 2004-03-04 2005-03-03 医薬化合物

Country Status (7)

Country Link
US (1) US7763234B2 (cg-RX-API-DMAC7.html)
EP (1) EP1729823B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007526300A (cg-RX-API-DMAC7.html)
CN (1) CN1925876A (cg-RX-API-DMAC7.html)
AT (1) ATE447417T1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017475D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005084715A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510683A (ja) * 2004-07-19 2008-04-10 ジーイー・ヘルスケア・リミテッド 改良n4キレーターコンジュゲート
JP2021515005A (ja) * 2018-03-01 2021-06-17 トライジェミナ, インコーポレイテッド 標識オキシトシンならびに製造および使用の方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036071A2 (en) * 2004-09-29 2006-04-06 Ge Healthcare As Urokinase plasminogen activator receptor targeted contrast agent
AU2005307195A1 (en) * 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
WO2010089757A2 (en) * 2008-11-07 2010-08-12 Usv Limited An improved process for synthesis of cyclic octapeptide
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018496A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2003006070A2 (en) * 2001-07-10 2003-01-23 Amersham Plc Improved chelator conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966896A (en) 1974-09-06 1976-06-29 Mallinckrodt, Inc. Radioimmunoassay for plasma renin activity
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
WO1993012819A1 (en) 1992-01-03 1993-07-08 Rhomed Incorporated Protein- and peptide-metal ion pharmaceutical applications
CA2269985A1 (en) 1996-10-28 1998-05-07 Aslak Godal Improvements in or relating to diagnostic/therapeutic agents
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
JP5043271B2 (ja) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
WO2002020610A2 (en) * 2000-09-07 2002-03-14 Biosynthema Inc. Conformationally constrained labeled peptides for imaging and therapy
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
NO20030115D0 (no) 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018496A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
WO2003006070A2 (en) * 2001-07-10 2003-01-23 Amersham Plc Improved chelator conjugates

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510683A (ja) * 2004-07-19 2008-04-10 ジーイー・ヘルスケア・リミテッド 改良n4キレーターコンジュゲート
JP2021515005A (ja) * 2018-03-01 2021-06-17 トライジェミナ, インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
JP2026035830A (ja) * 2018-03-01 2026-03-04 トニックス ファーマ リミテッド 標識オキシトシンならびに製造および使用の方法

Also Published As

Publication number Publication date
CN1925876A (zh) 2007-03-07
DE602005017475D1 (de) 2009-12-17
WO2005084715A2 (en) 2005-09-15
WO2005084715A3 (en) 2006-06-15
US20070297979A1 (en) 2007-12-27
EP1729823A2 (en) 2006-12-13
ATE447417T1 (de) 2009-11-15
US7763234B2 (en) 2010-07-27
EP1729823B1 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
JP5784911B2 (ja) ボンベシンアナログペプチドアンタゴニスト複合体
CN103288919B (zh) 受体(sstr2)-选择性生长抑素拮抗剂
CN102089321B (zh) 促生长素抑制素受体2拮抗剂
CA2452923C (en) Peptide-based compounds for targeting integrin receptors
US6126916A (en) Radiometal-binding peptide analogues
EP1991562A2 (en) Cancer imaging and treatment
CA2697949A1 (en) Cancer imaging and treatment
CN106573031A (zh) 双末端聚乙二醇化整合素‑结合肽及其使用方法
HU227640B1 (en) Kappa receptor opioid tetra peptides and pharmaceutical compositions comprising thereof
JP2010529957A (ja) 環状ペプチドcxcr4アンタゴニスト
EP3710068A1 (en) A double-labeled probe for molecular imaging and use thereof
JP2007510643A (ja) 医薬化合物
JP2006517539A (ja) 造影剤
US7763234B2 (en) Pharmaceutical compounds
US7431914B2 (en) Contrast agent
AU2005254915B2 (en) Peptide-based compounds
EP1257575B1 (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
CN1953772A (zh) 对血管紧张素ⅱ受体显像的造影剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124